Anatara Lifesciences Ltd
ANR.AX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.87M
Close$
$0.00
81.1% downside
Current Fair Value
81.1% downsideOvervalued by 81.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.87 Million |
|---|---|
| Enterprise Value | $1.40 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.69 |
| Outstanding Shares | 315,950,765 |
Return
| Return on Equity | -350.10% |
|---|---|
| Return on Assets | -303.65% |
| Return on Invested Capital | -395.23% |
Valuation & Multiples
| P/E Ratio | -2.65 |
|---|---|
| PEG | -48.99 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1.58 |
| Enterprise Value to EBIT | -0.5 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
February 24, 2027
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Anatara Lifesciences Ltd
7 employees
CEO: David Lionel Brookes Anatara Lifesciences Ltd is an Australian enterprise focused on researching, developing, and commercializing scientifically-validated therapies for digestive system ailments affecting both humans and animals. Its product portfolio includ...